Payment overview · 2025
General Payments
$264.51
14 reported records · 8 companies
Healthcare provider profile · identity verified
Leon A Driss, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SHOW LOW, AZ · NPI 1669445706
Verified facts
What the public records show
CMS Open Payments records show Leon A Driss, MD received $264.51 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $100.16 | 37.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.80 | 12.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25.75 | 9.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.66 | 9.7% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $22.36 | 8.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.50 | 7.4% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $19.22 | 7.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.06 | 7.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $264.51 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.84 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $35.12 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.80 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $25.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.66 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $22.36 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
50 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 570 | 183 |
| Levothyroxine Sodium | Levothyroxine Sodium | 422 | 131 |
| Lisinopril | Lisinopril | 388 | 127 |
| Metformin Hcl | Metformin Hcl | 379 | 122 |
| Losartan Potassium | Losartan Potassium | 377 | 129 |
| Amlodipine Besylate | Amlodipine Besylate | 296 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 264 | 87 |
| Furosemide | Furosemide | 239 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 236 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 224 | 75 |
| Omeprazole | Omeprazole | 223 | 72 |
| Gabapentin | Gabapentin | 220 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 68 |
| Pioglitazone Hcl | Pioglitazone Hcl | 194 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 163 | 60 |
| Jardiance | Empagliflozin | 160 | 56 |
| Warfarin Sodium | Warfarin Sodium | 154 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 146 | 73 |
| Alendronate Sodium | Alendronate Sodium | 119 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 39 |
| Spironolactone | Spironolactone | 116 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 38 |
| Eliquis | Apixaban | 111 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 109 | 38 |
| Allopurinol | Allopurinol | 104 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 100 | 34 |
| Metformin Hcl Er | Metformin Hcl | 99 | 32 |
| Carvedilol | Carvedilol | 89 | 30 |
| Simvastatin | Simvastatin | 88 | 31 |
| Montelukast Sodium | Montelukast Sodium | 82 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 33 |
| Prednisone | Prednisone | 80 | 58 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 23 |
| Glipizide | Glipizide | 61 | 20 |
| Ozempic | Semaglutide | 58 | 19 |
| Trazodone Hcl | Trazodone Hcl | 56 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | 11 |
| Famotidine | Famotidine | 50 | 13 |
| Ondansetron Odt | Ondansetron | 50 | 29 |
| Symbicort | Budesonide/Formoterol Fumarate | 50 | 21 |
| Tramadol Hcl | Tramadol Hcl | 50 | 17 |
| Potassium Chloride | Potassium Chloride | 48 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 32 |
| Sertraline Hcl | Sertraline Hcl | 47 | 16 |
| Synthroid | Levothyroxine Sodium | 47 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 23 |
| Bupropion Xl | Bupropion Hcl | 45 | 19 |
| Estradiol | Estradiol | 45 | 16 |
| Azithromycin | Azithromycin | 44 | 37 |
| Xarelto | Rivaroxaban | 44 | 13 |
| Celecoxib | Celecoxib | 43 | 20 |
| Januvia | Sitagliptin Phosphate | 43 | 13 |
| Lovastatin | Lovastatin | 42 | 14 |
| Meloxicam | Meloxicam | 42 | 16 |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Finasteride | Finasteride | 41 | 15 |
| Atenolol | Atenolol | 39 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 17 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 22 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | 13 |
| Levofloxacin | Levofloxacin | 34 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 23 |
| Cephalexin | Cephalexin | 30 | 20 |
| Topiramate | Topiramate | 30 | 12 |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Baclofen | Baclofen | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Digoxin | Digoxin | 20 | 11 |
| Pregabalin | Pregabalin | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | 12 |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 12 |
| Fluconazole | Fluconazole | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $264.51 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, DALVANCE, EVENITY, ISTURISA, Ozempic, Rybelsus, TRELEGY ELLIPTA, VOQUEZNA, VYVGART HYTRULO | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error